

Subject index

Volume 66 (2005)

- Alfacon1**; Interferon; SARS-corona; Antiviral; Therapy **66**, 99
- Alligator**; Antiviral; Complement; Crocodilian; Serum **66**, 35
- Amdoxovir**; DAPD; DXG; Pre-steady state; HIV-1 reverse transcriptase; Multi-drug resistance; Q151M **66**, 153
- Animal model**; hMPV; Human metapneumovirus; Cotton rats; Antiviral testing; Vaccine evaluation **66**, 57
- Antiviral activity**; Dengue virus; Flaviviruses; Sulfated polysaccharides; Viral entry **66**, 103
- Antiviral assay**; Chronic B hepatitis; HepG2; *Polygonum cuspidatum*; Polymerase chain reaction; TaqMan **66**, 29
- Antiviral defense**; Oyster; *Crassostrea gigas*; HSV-1; IPNV; VHSV; Hemolymph **66**, 147
- Antiviral effect**; Influenza; Cranberry; NDM **66**, 9
- Antiviral factor**; Virus resistance; Differential profile; *Penaeus japonicus* **66**, 39
- Antiviral testing**; hMPV; Human metapneumovirus; Cotton rats; Animal model; Vaccine evaluation **66**, 57
- Anti-viral therapy**; SARS-CoV; Ribavirin **66**, 81
- Antiviral**; Alligator; Complement; Crocodilian; Serum **66**, 35
- Antiviral**; Interferon; Alfacon1; SARS-corona; Therapy **66**, 99
- Antiviral**; Oleuropein; Olive leaf extract; VHSV; Viral membrane fusion **66**, 129
- Apoptosis**; HIV-1 protease; Saquinavir; Cell lysis; Cytopathogenicity **66**, 47
- Cell lysis**; HIV-1 protease; Saquinavir; Apoptosis; Cytopathogenicity **66**, 47
- Chronic B hepatitis**; Antiviral assay; HepG2; *Polygonum cuspidatum*; Polymerase chain reaction; TaqMan **66**, 29
- Cidofovir**; Mousepox infection; Interleukin-4; Immune suppression **66**, 1
- Complement**; Alligator; Antiviral; Crocodilian; Serum **66**, 35
- Coronavirus**; SARS; Ribavirin; Mizoribine **66**, 159
- Cotton rats**; hMPV; Human metapneumovirus; Animal model; Antiviral testing; Vaccine evaluation **66**, 57
- Cranberry**; Influenza; NDM; Antiviral effect **66**, 9
- Crassostrea gigas**; Oyster; Antiviral defense; HSV-1; IPNV; VHSV; Hemolymph **66**, 147
- Crocodilian**; Alligator; Antiviral; Complement; Serum **66**, 35
- Cytopathogenicity**; HIV-1 protease; Saquinavir; Cell lysis; Apoptosis **66**, 47
- DAPD**; Amdoxovir; DXG; Pre-steady state; HIV-1 reverse transcriptase; Multi-drug resistance; Q151M **66**, 153
- Dengue virus**; Flaviviruses; Antiviral activity; Sulfated polysaccharides; Viral entry **66**, 103
- Differential profile**; Antiviral factor; Virus resistance; *Penaeus japonicus* **66**, 39
- DXG**; DAPD; Amdoxovir; Pre-steady state; HIV-1 reverse transcriptase; Multi-drug resistance; Q151M **66**, 153
- Enterovirus 70**; VP1; Recombinant protein; Neutralizing antibody; Neutralization antigenic site **66**, 111
- Fd bacteriophage**; HIV-1; Tat; Inhibitory peptide; Nuclear-import **66**, 67
- Flaviviruses**; Dengue virus; Antiviral activity; Sulfated polysaccharides; Viral entry **66**, 103
- GB virus B**; Surrogate model system; Immortalization **66**, 165
- Hemolymph**; Oyster; *Crassostrea gigas*; Antiviral defense; HSV-1; IPNV; VHSV **66**, 147
- Hepatitis B virus**; Th lymphocytes; Interferon- γ ; Interleukin-12; Interleukin-18 **66**, 23
- HepG2**; Antiviral assay; Chronic B hepatitis; *Polygonum cuspidatum*; Polymerase chain reaction; TaqMan **66**, 29

- HIV**; Peptide nucleic acid (PNA); Proviral DNA; Latent infection **66, 13**
- HIV-1 protease**; Saquinavir; Cell lysis; Apoptosis; Cytopathogenicity **66, 47**
- HIV-1 reverse transcriptase**; DAPD; Amdoxovir; DXG; Pre-steady state; Multi-drug resistance; Q151M **66, 153**
- HIV-1**; 4-Phenyl-coumarins; Mesuol; LTR; NF- κ B **66, 137**
- HIV-1**; *Polygonum tinctorium*; *Sukumo* extract; HSV-1; Viral entry **66, 119**
- HIV-1**; Tat; Fd bacteriophage; Inhibitory peptide; Nuclear-import **66, 67**
- hMPV**; Human metapneumovirus; Cotton rats; Animal model; Antiviral testing; Vaccine evaluation **66, 57**
- HSV-1**; Oyster; *Crassostrea gigas*; Antiviral defense; IPNV; VHSV; Hemolymph **66, 147**
- HSV-1**; *Polygonum tinctorium*; *Sukumo* extract; HIV-1; Viral entry **66, 119**
- Human metapneumovirus**; hMPV; Cotton rats; Animal model; Antiviral testing; Vaccine evaluation **66, 57**
- Immortalization**; GB virus B; Surrogate model system **66, 165**
- Immune suppression**; Cidofovir; Mousepox infection; Interleukin-4 **66, 1**
- Influenza**; Cranberry; NDM; Antiviral effect **66, 9**
- Inhibitory peptide**; HIV-1; Tat; Fd bacteriophage; Nuclear-import **66, 67**
- Interferon**; Alfacon1; SARS-corona; Antiviral; Therapy **66, 99**
- Interferon- γ** ; Hepatitis B virus; Th lymphocytes; Interleukin-12; Interleukin-18 **66, 23**
- Interleukin-12**; Hepatitis B virus; Th lymphocytes; Interferon- γ ; Interleukin-18 **66, 23**
- Interleukin-18**; Hepatitis B virus; Th lymphocytes; Interferon- γ ; Interleukin-12 **66, 23**
- Interleukin-4**; Cidofovir; Mousepox infection; Immune suppression **66, 1**
- IPNV**; Oyster; *Crassostrea gigas*; Antiviral defense; HSV-1; VHSV; Hemolymph **66, 147**
- Latent infection**; Peptide nucleic acid (PNA); Proviral DNA; HIV **66, 13**
- LTR**; 4-Phenyl-coumarins; Mesuol; HIV-1; NF- κ B **66, 137**
- Mesuol**; 4-Phenyl-coumarins; HIV-1; LTR; NF- κ B **66, 137**
- Mizoribine**; SARS; Coronavirus; Ribavirin **66, 159**
- Mousepox infection**; Cidofovir; Interleukin-4; Immune suppression **66, 1**
- Multi-drug resistance**; DAPD; Amdoxovir; DXG; Pre-steady state; HIV-1 reverse transcriptase; Q151M **66, 153**
- NDM**; Influenza; Cranberry; Antiviral effect **66, 9**
- Neutralization antigenic site**; Enterovirus 70; VP1; Recombinant protein; Neutralizing antibody **66, 111**
- Neutralizing antibody**; Enterovirus 70; VP1; Recombinant protein; Neutralization antigenic site **66, 111**
- NF- κ B**; 4-Phenyl-coumarins; Mesuol; HIV-1; LTR **66, 137**
- Nuclear-import**; HIV-1; Tat; Fd bacteriophage; Inhibitory peptide **66, 67**
- Oleuropein**; Olive leaf extract; VHSV; Antiviral; Viral membrane fusion **66, 129**
- Olive leaf extract**; Oleuropein; VHSV; Antiviral; Viral membrane fusion **66, 129**
- Oyster**; *Crassostrea gigas*; Antiviral defense; HSV-1; IPNV; VHSV; Hemolymph **66, 147**
- Penaeus japonicus***; Antiviral factor; Virus resistance; Differential profile **66, 39**
- Peptide nucleic acid (PNA)**; Proviral DNA; Latent infection; HIV **66, 13**
- 4-Phenyl-coumarins**; Mesuol; HIV-1; LTR; NF- κ B **66, 137**
- Polygonum cuspidatum***; Antiviral assay; Chronic B hepatitis; HepG2; Polymerase chain reaction; TaqMan **66, 29**
- Polygonum tinctorium***; *Sukumo* extract; HIV-1; HSV-1; Viral entry **66, 119**
- Polymerase chain reaction**; Antiviral assay; Chronic B hepatitis; HepG2; *Polygonum cuspidatum*; TaqMan **66, 29**
- Pre-steady state**; DAPD; Amdoxovir; DXG; HIV-1 reverse transcriptase; Multi-drug resistance; Q151M **66, 153**
- Proviral DNA**; Peptide nucleic acid (PNA); Latent infection; HIV **66, 13**
- Q151M**; DAPD; Amdoxovir; DXG; Pre-steady state; HIV-1 reverse transcriptase; Multi-drug resistance **66, 153**
- Recombinant protein**; Enterovirus 70; VP1; Neutralizing antibody; Neutralization antigenic site **66, 111**
- Ribavirin**; Anti-viral therapy; SARS-CoV **66, 81**
- Ribavirin**; SARS; Coronavirus; Mizoribine **66, 159**
- Saquinavir**; HIV-1 protease; Cell lysis; Apoptosis; Cytopathogenicity **66, 47**
- SARS**; Coronavirus; Ribavirin; Mizoribine **66, 159**
- SARS-corona**; Interferon; Alfacon1; Antiviral; Therapy **66, 99**
- SARS-CoV**; Anti-viral therapy; Ribavirin **66, 81**
- Serum**; Alligator; Antiviral; Complement; Crocodilian **66, 35**
- Sukumo* extract**; *Polygonum tinctorium*; HIV-1; HSV-1; Viral entry **66, 119**
- Sulfated polysaccharides**; Dengue virus; Flaviviruses; Antiviral activity; Viral entry **66, 103**
- Surrogate model system**; GB virus B; Immortalization **66, 165**
- TaqMan**; Antiviral assay; Chronic B hepatitis; HepG2; *Polygonum cuspidatum*; Polymerase chain reaction **66, 29**

Tat; HIV-1; Fd bacteriophage; Inhibitory peptide; Nuclear-import **66**, 67

Th lymphocytes; Hepatitis B virus; Interferon- γ ; Interleukin-12; Interleukin-18 **66**, 23

Therapy; Interferon; Alfacon1; SARS-corona; Antiviral **66**, 99

Vaccine evaluation; hMPV; Human metapneumovirus; Cotton rats; Animal model; Antiviral testing **66**, 57

VHSV; Oleuropein; Olive leaf extract; Antiviral; Viral membrane fusion **66**, 129

VHSV; Oyster; *Crassostrea gigas*; Antiviral defense; HSV-1; IPNV; Hemolymph **66**, 147

Viral entry; Dengue virus; Flaviviruses; Antiviral activity; Sulfated polysaccharides **66**, 103

Viral entry; *Polygonum tinctorium*; *Sukumo* extract; HIV-1; HSV-1 **66**, 119

Viral membrane fusion; Oleuropein; Olive leaf extract; VHSV; Antiviral **66**, 129

Virus resistance; Antiviral factor; Differential profile; *Penaeus japonicus* **66**, 39

VP1; Enterovirus 70; Recombinant protein; Neutralizing antibody; Neutralization antigenic site **66**, 111